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A B S T R A C T
Acute lower respiratory tract infections (ALRI) caused by respiratory syncytial virus (RSV) are associated with a
severe disease burden among infants and elderly patients. Treatment options are limited. While numerous drug
candidates with different viral targets are under development, the utility of RSV entry inhibitors is challenged by a
low resistance barrier and by single mutations causing cross-resistance against a wide spectrum of fusion inhibitor
chemotypes. We developed a cell-based screening assay for discovery of compounds inhibiting infection with primary
RSV isolates. Using this system, we identified labyrinthopeptin A1 and A2 (Laby A1/A2), lantibiotics isolated from
Actinomadura namibiensis, as effective RSV cell entry inhibitors with IC50s of 0.39 μM and 4.97 μM, respectively, and
with favourable therapeutic index (>200 and > 20, respectively). Both molecules were active against multiple RSV
strains including primary isolates and their antiviral activity against RSV was confirmed in primary human airway
cells ex vivo and a murine model in vivo. Laby A1/A2 were antiviral in prophylactic and therapeutic treatment
regimens and displayed synergistic activity when applied in combination with each other. Mechanistic studies
showed that Laby A1/A2 exert virolytic activity likely by binding to phosphatidylethanolamine moieties within the
viral membrane and by disrupting virus particle membrane integrity. Probably due to its specific mode of action,
Laby A1/A2 antiviral activity was not affected by common resistance mutations to known RSV entry inhibitors.
Taken together, Laby A1/A2 represent promising candidates for development as RSV inhibitors. Moreover, the cell-
based screening system with primary RSV isolates described here should be useful to identify further antiviral agents.
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Acute lower respiratory tract infections (ALRI) are one of the
leading causes of childhood morbidity and mortality (Liu et al., 2016;
Theodoratou et al., 2014). RSV is the most common cause of ALRI in
infants and the most frequent cause of hospitalization among those
younger than one year (Leader and Kohlhase, 2002; Olchanski et al.,
2018). It is responsible for approximately 33 million episodes of ALRI in
children younger than five years, leading to 3.2 million hospitalizations
and ca. 60,000 in-hospital-deaths (Shi et al., 2017). Moreover, RSV
causes substantial global disease burden in elderly patients (Shi et al.,
2019).
To date, only two antiviral treatment options are available for
clinical use. Ribavirin, a nucleoside analogue with broad activity
against multiple viruses and proven in vitro efficacy against RSV, is
approved for inhalative treatment of RSV-infected infants. However,
due to lack of clinical efficacy in addition to possible teratogenic side
effects its routine use is no longer recommended (Mazur et al., 2015).
Palivizumab, a RSV fusion protein-targeting monoclonal antibody for
prophylactic passive immunization against RSV infection is available.
But Palivizumab reduces hospitalization rates only by 55% and cannot
be broadly applied due to its high costs (IMpact, 1998). Thus, novel
therapeutic strategies to treat and/or prevent severe RSV infection are
needed.
RSV is an enveloped virus with a non-segmented, negative strand
RNA genome. It is classified in the family of Pneumoviridae and the
genus Orthopneumovirus (Afonso et al., 2016). The viral attachment
glycoprotein (G) and the fusion protein (F) mediate infection of re-
spiratory cells. Upon cell entry, the viral RNA genome serves as tem-
plate for transcription of ten capped and polyadenylated mRNAs and
for genome replication. Transcription and genome replication are cat-
alyzed by a ribonucleoprotein complex consisting of the viral nucleo-
capsid (N) protein that tightly binds to viral genomic and antigenomic
RNAs, the viral L protein that serves as catalytic centre of the RNA-
dependent RNA polymerase, and the phosphoprotein (P). The M2-1
protein is an essential transcription processivity factor needed for
production of full length mRNAs (Collins et al., 1996). A range of RSV
inhibitors is in various stages of pre-clinical and clinical development
including fusion inhibitors, nucleosidic and non-nucleosidic polymerase
inhibitors, as well as G, N and M2-1-targeting antivirals (Bailly et al.,
2016; Cockerill et al., 2019; Gaillard et al., 2017; Ouizougun-Oubari
et al., 2015). Some of these molecules, including fusion inhibitors like
Presatovir (GS-5806) and JNJ-678 have progressed to phase II clinical
trials and have proven efficacy in human RSV challenge studies
(Cockerill et al., 2019; DeVincenzo et al., 2014). However, the barrier
to RSV fusion inhibitor resistance is rather low and several single mu-
tations cause pronounced viral cross-resistance to structurally diverse
fusion inhibitors, possibly compromising utility of this type of RSV
entry inhibitors (Battles et al., 2016; Yan et al., 2014).
Here, we describe a novel cell-based screening approach for iden-
tification of RSV inhibitors and identify Laby A1/A2 as a novel class of
RSV-targeting cell entry inhibitors. We show that Laby A1 and A2, class
III lanthipeptides, isolated from Actinomadura namibiensis DSM6313
(Meindl et al., 2010; Muller et al., 2010; Rupcic et al., 2018), inhibit
RSV entry by disrupting the integrity of RSV particles. Because the
antiviral activity of Laby A1/A2 is not affected by resistance to Pali-
vizumab or clinical-stage RSV fusion inhibitors, these molecules are
interesting compounds for development as RSV inhibitors.
2. Materials and methods
2.1. Media, cells, virus and compounds
All cell culture media were obtained from Life technologies (Thermo
Fisher Scientific, Waltham, MA). FCS was obtained from Capricorn
Scientific (Ebsdorfergrund, Germany) and heat inactivated for
30 min at 56 °C. HEp-2 cells (CCL-23), A549 cells (CCL-185), 293T cells
(HEK293T/17; CRL-11268), RSV-A2 (VR-1540) and RSV-A long strains
(VR-26) were originally obtained from ATCC (Manassas, VA).
Recombinant viruses rHRSV-A-Luc, rHRSV-A-GFP and rHRSV-B05
eGFP were described recently (Lemon et al., 2015; Rameix-Welti et al.,
2014). Laby A1 and A2 were produced and isolated from actinomycete
Actinomadura namibiensis DSM 6313 using a standardized submerged
liquid cultivation in 10 L bioreactors (BBI Biotech, Berlin) and an im-
proved down-stream procedure as described before (Rupcic et al.,
2018). Palivizumab was purchased from AbbVie Ltd. (North Chicago,
IL) and Ribavirin was purchased from Sigma-Aldrich (Steinheim, Ger-
many). BMS-433771 was a kind gift from Richard Karl Plemper
(Georgia State University, Atlanta, GA, USA).
2.2. Cell cultures
All cells were cultured in a humidified incubator at 37 °C and 5%
CO2. HEp-2 cells were grown in Advanced MEM and A549 cells in F12K
NutMix, both supplemented with 10% heat-inactivated fetal bovine
serum (FCS), non-essential amino acids (Gibco), 2 mM L-glutamine
(Gibco), 100 U/ml Penicillin and 100 U/ml Streptomycin (Thermo
Fisher Scientific, Waltham, MA). 293T cells were grown in DMEM
media supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml
Penicillin, 100 U/ml Streptomycin and non-essential amino acids.
Primary human airway epithelia cells (HuAEC) were isolated and cul-
tivated as described elsewhere (Jonsdottir and Dijkman, 2015).
2.3. Primary hRSV isolates
The primary hRSV isolates were collected from children below the
age of five years with confirmed RSV infection, hospitalized at
Hannover Medical School. Viruses were isolated from nasopharyngeal
aspirates and further cultivated on HEp-2 cells. All caregivers gave in-
formed consent for the donation of nasopharyngeal aspirates, and all
steps were conducted in compliance with good clinical and ethical
practice and approved by the local ethical committee at Hannover
Medical School (permission number 63090/2012).
2.4. Screening assay
A HEp-2 cell line expressing a firefly luciferase (HEp-2-F-Luc cells)
was generated via lentiviral gene transfer using a self-inactivating
vector pWPI-F-Luc transducing firefly luciferase and subsequent selec-
tion of transduced cells in the presence of blasticidine (5 μg/ml). 293T
cells were transfected with envelope protein expression construct pcz-
VSV-G (Kalajzic et al., 2001), HIV Gag-Pol expression construct pCMV-
ΔR8.74 (Dull et al., 1998) and firefly transducing vector pWPI-F-Luc-
BLR. 48 h post transfection, cell-free supernatant was harvested and
used to transduce HEp-2 cells. Transduced cells were passaged in the
presence of blasticidine. For compound screening, cells were seeded at
a density of 1 × 10e4 cells/well onto a 96-well plate. 24 h post seeding,
cells were infected with a clinical RSV strain (RSV-ON1-H1) at an MOI
of 3 in the presence of 10 μM compound. 72 h post inoculation, cell
viability as direct correlate to virus replication and/or cytotoxicity was
analyzed using a firefly luciferase assay and a plate luminometer
(Centro XS LB960, Berthold, Germany).
2.5. In vitro infection assay
Cells were seeded at a density of 1 × 10e4 cells/well in a 96-well
plate 24 h prior to infection. Virus inoculation was performed at 37 °C
for 4 h prior to medium change. If not stated otherwise, number of
infection events was analyzed 24 h post inoculation.
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2.6. Intracellular FACS analysis
Cells were detached by trypsinization and fixed in PFA-containing
fixation buffer (0.5% paraformaldehyde, 1% FCS in PBS) for 30 min
prior to permeabilization (0.1% Saponin in PBS) for 20 min at 4 °C.
Intracellular RSV phosphoprotein was stained by addition of mono-
clonal anti-RSV-P antibody (26D6G5C6; final concentration 0.002 mg/
ml in permeabilization buffer) (Haid et al., 2015) for 30 min and sub-
sequent washing steps. After addition of a fluorescently labelled sec-
ondary anti-mouse antibody (Alexa Fluor488; final concentration
0.01 mg/ml in permeabilization buffer; Thermo Fisher Scientific, Wal-
tham, USA) flow cytometry was performed using an Accuri C6 machine
(BD, Heidelberg, Germany) followed by data analysis using FlowJo
software (Tree Star, Ashland, USA).
2.7. RSV pseudoparticles
Lentiviral based RSV pseudoparticles were produced as described
elsewhere (Haid et al., 2015). In brief, 1.5 × 10e6 293T cells were
seeded into a 6-cm diameter plate and transfected with plasmids en-
coding for lentiviral gag-pol pCMV-ΔR8.74 (Dull et al., 1998), a re-
porter (pWPI-F-Luc-BLR or pWPI-R-Luc-BLR) as well as the RSV gly-
coproteins RSV-SH, -G and a c-terminally truncated -F (pcDNA-hRSV-
SH, pcDNAhRSV-G or pcDNA-hRSV-F-trc). 30 h post transfection (for
hRSV-F K394R mutant already 24 h post transfection), supernatants
containing lentiviral particles were harvested, cleared of cell debris and
preincubated with the drugs for 30 min prior to infection of A549 cells.
72 h post infection, cells were lysed and luciferase activity was analyzed
using a tube luminometer (Lumat LB 9507; Berthold, Freiburg, Ger-
many).
2.8. Liposome assays
Lipids purchased from Avanti Polar Lipids (Alabaster, AL) were
dissolved as 10 mM stocks in 67% chloroform/33% methanol and li-
posomes were generated as described elsewhere (Henriques et al.,
2011). HEp-2 cells were seeded on 96-well plates (1.5 × 10e4 cells/
well) one day prior to infection. On day of infection, cells were pre-
incubated with medium containing liposomes of different composition
together with indicated concentrations of Laby A1/A2 for 30 min at
37 °C prior to addition of RSV-ON1-H1 virus (MOI 0.2) or rHRSV-A-Luc
virus (MOI 0.1). Liposomes were used at a final concentration of
100 μM (20% DOPS/40% DOPC/40% DOPE and 20% DOPS/80%
DOPC liposomes) or 10 μM (60% DOPC/40% DOPE and 100% DOPC
liposomes), respectively. 24 h post infection, the number of RSV-ON1-
H1-infected cells was analyzed using an intracellular FACS staining
against the RSV phosphoprotein RSV-P. Supernatant of rHRSV-A-Luc
virus was changed to fresh medium after 4 h and 24 h post infection
cells were lysed for luciferase quantification using a plate luminometer
(Berthold, Freiburg, Germany).
2.9. Proteinase K protection assay
The proteinase K protection assay was performed as described
elsewhere (Lawless-Delmedico et al., 2000; Mader et al., 2000). In brief,
liposomes either existing of phosphatidylcholine alone (DOPC) or a
60:40 ratio of phosphatidylcholine and phosphatidylethanolamine
(DOPE) were preincubated with 40 μM Laby A1 for 30 min at room
temperature. After 30 min of incubation, either conditioned media or
RSV-ON1-H1 virus was added for another 30 min prior to addition of
2 μg/ml proteinase K (Roche, Basel, Switzerland) for 1h on ice. Addi-
tion of 5 mM PMSF (AppliChem, Darmstadt, Germany) and heating of
the sample for 10 min at 98 °C was used to terminate proteinase K
digestion. Virus treated with 2% (v/v) of the detergent Trition X-100
served as positive control. Samples were further analyzed on an 11%
SDS-PAGE followed by Western Blot analysis using an antibody against
the RSV phosphoprotein P (26D6G5C6) and a HRP-coupled secondary
anti-mouse antibody (Sigma Aldrich, Steinheim, Germany). Detection
of bound antibodies was performed with the ECL prime detection re-
agent (GE Healthcare, Freiburg, Germany) on a ChemoStar machine
(Intas, Göttingen, Germany).
2.10. Drug-drug interaction
One day before infection, 1x10e4 HEp-2 cells were seeded in 96-
well plates and infected with rHRSV-A-Luc virus (Rameix-Welti et al.,
2014) at an MOI of 0.1 in the presence of various concentrations of
different drug combinations. 24 h post infection, cells were lysed and
luciferase activity was analyzed using a plate luminometer (Berthold,
Freiburg, Germany). Synergistic, additive or inhibitory effects were
determined using equations described by Prichard and Shipman (1990).
2.11. Quantitative RT-PCR to detect viral RNA
Viral RNA was isolated from infected cells or from cell culture su-
pernatant of RSV infected well-differentiated primary human airway
epithelial cells using a NucleoSpin RNA kit (Macherey-Nagel, Düren,
Germany) or a high pure viral RNA kit (Roche, Mannheim, Germany).
2 μl of purified RNA was subsequently used for quantitative RT-PCR
analysis using a one-step RT-PCR LightCycler480 RNA Master
Hydrolysis Probe kit and a LightCycler480 machine (Roche, Mannheim,
Germany). RSV-A specific probe (6FAM-CACCATCCAACGGAGCACAG
GAGAT-BBQ; TIB Molbiol, Berlin, Germany) and primers (s-RSV-A 5'-
AGATCAACTTCTGTCATCCAGCAA-3'; as-RSV-A 5'-TTCTGCACATCATA
ATTAGGAG-3'; MWG-Biotech, Martinsried, Germany) were used as
published elsewhere (Gunson et al., 2005). RSV-B specific viral RNA
was detected using a RSV-B specific probe (YAK-ATGCTATGTCCAGG
TTAGGAAGGG-BBQ; TIB Molbiol, Berlin, Germany) and primers (s-
RSV-B 5'-GTCATAAATTCACAGGATTAATAGGTA-3'; as-RSV-B 5'- GCA
TGATATCCAGCATCTTTAAGTA-3'; MWG-Biotech, Martinsried, Ger-
many). Amplification was performed for 40 cycles at 62 °C for RSV-A
and 55 °C for RSV-B respectively and RSV copy numbers were calcu-
lated using in run standard curves.
2.12. Infection of well-differentiated human air-liquid interface cultures
Human airway epithelia cells of bronchial origin (hBEC) were iso-
lated from explanted human lungs as described elsewhere (Jonsdottir
and Dijkman, 2015). In brief, human tissue was enzymatically digested
for 48 h at 4 °C prior to isolation of epithelial cells from the lumen of the
bronchus. Cells were seeded on collagen-coated flasks for proliferation
prior to seeding on collagen-coated transwells with 0.4 μM pore
polyester membrane inserts (Corning Costar). Upon confluency, the
medium from the apical compartment was removed and cells were
washed with HBSS (Thermo Fisher Scientific, Waltham, MA) and ex-
posed to the air. Medium change in the basolateral compartment was
performed every other day and the apical cell layer was washed once
weekly with HBSS until cells differentiated into a well-differentiated
human airway epithelium. At day of infection, cells were apically wa-
shed twice with HBSS prior to addition of RSV reporter virus (rHRSV-
B05 eGFP or rHRSV-A-GFP) to the apical side for 2 h at 37 °C. Virus
inoculum was removed and cells were washed two times with HBSS
followed by basolateral medium change. For the prophylactic experi-
ment setup, newly produced and released viruses were harvested on a
daily basis by addition of 100 μl HBSS to the apical compartment for
30 min. Viral RNA was isolated using a high pure viral RNA kit (Roche,
Mannheim, Germany) and analyzed on a LightCycler480 machine
(Roche, Mannheim, Germany). For therapeutic treatment, cells were
infected with rHRSV-A-GFP 8 h prior to start of treatment and treat-
ment was performed twice daily. Therefore, Laby A1 and A2 were di-
luted in HBSS and cells were treated for 1 h from the apical side. 72 h
post infection, cells were lysed and total RNA was isolated (Macherey-
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Nagel, Düren, Germany) and analyzed on a LightCycler 480 machine
(Roche, Mannheim, Germany). All patients gave informed consent for
the donation of lung tissue samples, and all steps were conducted in
compliance with good clinical and ethical practice and approved by the
local ethical committee at Hannover Medical School (permission
number 3346/2016).
2.13. Animal studies and ethics statement
BALB/cOlaHsd mice were purchased from ENVIGO and housed with
food and water ad libitum under specific pathogen free conditions at the
animal facilities of Twincore, Hannover. All experiments were con-
ducted in compliance with good animal practice as defined by the
Federation of Laboratory Animal Science Associations (FELASA) and
German welfare regulations and approved by the Lower Saxony State
Office for Consumer Protection and Food Safety (LAVES, permission
number 33.9-42502-04-17/2416).
14 week old female mice were infected with 1.9 × 10e5 PFU of
rHRSV-A-Luc or PBS intranasally. Starting 1 h before infection, mice
were treated intranasally with 30 μl of 2 mg/ml of Laby A1/A2 or ve-
hicle control (20% DMSO, 80% PBS) once daily. Every second day, in
vivo imaging of luciferase-based luminescence was measured using an in
vivo optical imaging system (IVIS SpectrumCT; Perkin Elmer) after in-
tranasal delivery of 30 μl of 10 mM D-Luciferin in PBS. For all treat-
ments, infections and luciferase measurements, mice were anesthetized
with Isoflurane. At the end of the experiments, mice were anesthetized
with Ketamin (100 g/kg BW) and Xylazin (10 g/kg BW) and perfused
with PBS. Lungs were extracted for histological and flow cytometric
analysis.
3. Results and discussion
3.1. HEp-2-F-Luc reporter cells for screening of RSV inhibitors with primary
isolates
To enable rapid identification of RSV inhibitors by screens with a
primary clinical RSV isolate, we transduced HEp-2 cells with a lentiviral
vector encoding a firefly luciferase reporter gene. The resulting HEp-2-
F-Luc cells constitutively express firefly luciferase (F-Luc) and therefore
the amount of F-Luc produced is proportional to the number of viable
cells. Since RSV lytically infects HEp-2 cells, inoculation of HEp-2-F-Luc
cells results in cell killing and subsequent elimination of luciferase re-
porter signal unless a non-cytotoxic RSV inhibitor prevents viral in-
fection, replication and spread. The dynamic range of the assay com-
prises approximately two orders of magnitude, which permits robust
and accurrate quantification of even minor inhibitory effects. The
principle of the screening assay is depicted in Fig. 1A. As expected,
Ribavirin dose-dependently inhibited infection of HEp-2-F-Luc cells
with a primary RSV-A isolate (RSV-ON1-H1). The antiviral effect was
evident from maintenance of cell viability in RSV-ON1-H1 inoculated
HEp-2-F-Luc cells as visualized by crystal violet staining (Fig. 1B).
Notably, addition of Ribavirin also dose dependently increased de-
tectable luciferase expression (Fig. 1C), and at a level of 100 μM Ri-
bavirin the reporter signal reached ca. 50% of the signal in uninfected
control cells (Fig. 1C).
Next, we used this assay to screen a small library of natural products
with proven biological activity (Gentzsch et al., 2011) for inhibitors of
RSV-ON1-H1 infection. Palivizumab and varying doses of Ribavirin
were used as control and effectively restored luciferase activity upon
virus infection (Fig. 1D). Among the tested compounds, Laby A1 and A2
showed the greatest antiviral effect maintaining luciferase reporter
expression at 76% and 62% of uninfected control cells. Notably, Ferir
et al. had previously described antiviral activity of Laby A1 against HIV-
1 and HSV-1, suggesting a broad antiviral activity (Ferir et al., 2013).
However, an antiviral activity of Laby A2 had not yet been described
and an activity against a respiratory virus had not been reported for
both Laby A1 and A2. Next, we confirmed the antiviral activity of these
two lanthipeptides by inoculation of HEp-2 cells with RSV-ON1-H1 in
presence of varying doses of these compounds. Infected cells were
quantified by intracellular flow cytometry of virus-expressed P protein
(Fig. 1E). Using this direct virus detection assay, we confirmed the
antiviral activity of both molecules with an IC50 of 0.39 μM for Laby A1
and of 4.97 μM for Laby A2, respectively. The cytotoxic concentration
50% (CC50) for Laby A1 was 79 μM and could not be determined for
Laby A2 due to a limited solubility of this compound beyond 100 μM
(Fig. 1F). Collectively, these results show that Laby A1 and A2 effec-
tively inhibit RSV infection in cell culture in a low micromolar range
and with a therapeutic index of 204 for Laby A1 and >20 for Laby A2,
respectively.
3.2. Laby A1/A2 inhibit RSV entry through acting on virus particles
The effect of Laby A1/A2 on the RSV lifecycle was determined
using time of addition experiments and cell entry assays with lenti-
viral pseudotypes (Haid et al., 2015) (Fig. 2). HEp-2 cells were either
pretreated with Laby A1/A2, heparin or Palivizumab, or these
compounds were present during RSV-ON1-H1 inoculation or com-
pounds were added directly after removal of the inoculum for an-
other 4 h (Fig. 2A and B). Comparable to the cell entry inhibitors
Palivizumab and heparin, LabyA1/A2 only inhibited RSV-ON1-H1
infection when present during inoculation (Fig. 2A). Moreover, a
more time-resolved assay revealed that RSV-ON1-H1 infection is
essentially resistant to addition of Laby A1/A2, when these com-
pounds are added 90 min after virus inoculation (Fig. 2B). When
A549 cells were infected with lentiviral pseudotypes carrying either
the G protein of the vesicular stomatitis virus (VSV-G), RSV-F protein
or RSV-F, -G and -SH proteins, the infection was dose-dependently
blocked by Laby A1/A2 (Fig. 2C). Finally, RSV-ON1-H1 particles
were incubated with Laby A1 or A2, with Ribavirin or Palivizumab
for 30 min. Subsequently, residual virus infectivity was quantified by
serial dilution end point titration and reported as tissue culture in-
fectious dose 50% (TCID50) (Fig. 2D). Similar to Palivizumab, which
directly binds to the F protein of virus particles, Laby A1/A2 also
inhibited RSV infection after pre-incubation of RSV particles. Col-
lectively, these results show that Laby A1/A2 inhibit RSV cell entry,
likely by directly acting on RSV particles.
3.3. Laby A1 and A2 disrupt RSV particle integrity
Recently, Prochnow et al. reported an antiviral activity of Laby
A1/A2 against dengue virus and they noted that Laby A1/A2 speci-
fically interact with the membrane lipid phosphatidylethanolamine
(PE) to exert their antiviral effect (Prochnow et al., 2020). To in-
vestigate if Laby A1 and A2 act on RSV particles and inhibit their
infectivity also through binding to PE, we prepared unilamellar ve-
sicles composed of phosphatidylserine (PS) together with PE and
phosphatidylcholine (PC) or, as control, PC and PS. Subsequently,
HEp-2 cells were inoculated with RSV-ON1-H1 in presence of in-
creasing doses of Laby A1 or A2 either in the absence of liposomes or
in the presence of PS/PC/PE or PS/PC-containing liposomes
(Fig. 3A). Addition of PS/PC-containing liposomes did not change
the antiviral activity of Laby A1 or A2. In contrast, in presence of PS/
PC/PE-liposomes the antiviral activity of both Laby A1 and A2 was
strongly attenuated. Liposomes also interfered with the antiviral ef-
fect of Laby A1 when they were composed of PC and PE only, ruling
out an important role of PS (Fig. 3B). These results suggest that ex-
cess PE binding sites on the liposomes compete for binding of Laby
A1 and A2, thereby reducing their antiviral activity. Next, we ex-
amined whether addition of Laby A1 destabilizes the membrane of
RSV particles and whether addition of PE-containing liposomes res-
cues virus membrane destabilization. To this end, we used a pro-
teolytic protection assay that quantifies the resistance of the virus
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Fig. 1. Identification and characteriza-
tion of Laby A1/A2 as anti-RSV drugs. A)
Screening principle. HEp-2 cells expres-
sing a firefly luciferase reporter gene
(HEp-2-F-Luc cells) were infected with
RSV. Infection leads to cell lysis thereby
decreasing F-Luc expression. (B) Cell
survival visualized by crystal violet
staining. HEp-2-F-Luc cells were infected
with RSV-ON1-H1 in the presence of in-
dicated drugs. 72 h post inoculation cells
were fixed and stained with 1% crystal
violet solution. Known inhibitors of RSV
infection (Ribavirin and Palivizumab)
rescued cell survival, visible by the dark
violet staining. Puromycin A, a transla-
tion inhibitor, killed the cells. (C)
Quantification of dose-dependent in-
hibitory effect of Ribavirin. D) HEp-2-F-
Luc cells were infected with RSV-ON1-
H1 (MOI 3) in the presence of com-
pounds (Gentzsch et al., 2011) and sur-
vival of cells was analyzed 72 h later.
(RLU: relative light unit). RLU counts
were normalized to uninfected control
cells and are given as percentage of cell
viability. Mean of 2 independent ex-
periments and standard deviation are
given. One sample t-test comparing all
sample means to hypothetical 100% cell
survival without correction for multiple
comparisons. *, p < 0.05; **, p < 0.01;
***, p < 0.001; n.s., not significant. The
dotted line indicates signal of infected
control cells, the dashed line marks
100% cell survival. E) HEp-2 cells were
inoculated with RSV-ON1-H1 in the
presence of indicated concentrations of
compounds. 24 h post infection, an in-
tracellular FACS analysis detecting RSV-
P was performed. The number of RSV-
infected cells was normalized to solvent-
treated control. Mean values of 3 in-
dependent experiments with standard
deviation is given. F) Cytotoxicity of
Laby A1/A2 was analyzed in HEp-2-F-
Luc cells by incubating the cells with the
indicated concentrations of compounds
for 72 h prior to measurement of firefly
luciferase activity. Mean values of 3 in-
dependent experiments normalized to
solvent control and standard deviation is
given.
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particle associated P protein to exogenously added proteinase K di-
gestion (Fig. 3C). RSV particles contain a lipid membrane, and
therefore P protein, which is associated with the polymerase com-
plex, is not accessible to exogenously added proteinase K (Fig. 3C;
line 8), unless the viral membrane is disrupted, as for instance by
treatment with the detergent Triton X-100 (line 16). RSV-ON1-H1
particles were incubated with proteinase K in either presence or
absence of Laby A1 that had been preincubated with liposomes of
different composition and concentration. When RSV particles were
incubated with proteinase K in the absence of Laby A1 (lane 8), P
protein was readily detectable. In contrast, presence of Laby A1 in-
creased the P protein susceptibility to proteinase K (line 9). Co-in-
cubation of particles with proteinase K and Triton X-100 caused
degradation of P protein to a level below the detection limit of our
assay (line 16). Addition of PE-containing liposomes protected P
protein from degradation in a dose dependent manner (line 10, line
12, line 14), whereas PC-containing liposomes were less potent in
protecting the viral particles from proteinase K digestion (line 11,
line 13, line 15). These results suggest that Laby A1 likely inhibit
RSV particle infectivity by binding to PE within the particle mem-
brane and by disrupting the viral lipid envelope. The observation
that addition of PE- but not PC-liposomes competes with the antiviral
activity of both Laby A1 and Laby A2 supports the notion that an
interaction between Laby A1/A2 and virus particle associated PE is
critical for the antiviral activity. In turn, the abundance and acces-
sibility of PE in the lipid membrane of virus particles may govern
susceptibility of virus particles to Laby A1/A2. Along similar lines,
the concentration of PE in cellular membranes may influence Laby
A1/A2 cytotoxic effects. It is worth mentioning that both Laby A1
and A2 have favourable therapeutic indices (204 and > 20 for A1
and A2, respectively). The pronounced selectivity for disruption of
virus particles over cytotoxicity could be related to differential
Fig. 2. Laby A1/A2 inhibits RSV entry. A) Experimental setup. HEp-2 cells were either pretreated (dark grey bar), treated during RSV-ON1-H1 virus inoculation
(black bar) or treated after virus infection (light grey bar) with indicated concentrations of compounds for 4 h. 24 h post infection, the number of RSV-positive cells
was determined by intracellular RSV-P protein FACS staining. Data are given as percentage of solvent control. Repeated measures 2way ANOVA followed by Tukey's
multiple comparison correction, with time of addition means compared within each treatment. Mean values and standard deviation of 3 independent experiments are
depicted. B) Schematic depiction of experimental setup. HEp-2 cells were incubated with RSV-ON1-H1 virus at 4 °C for 1 h to allow virus attachment and binding.
Unbound virus particles were subsequently removed by PBS washes, pre-warmed media was added and the cells were shifted to 37 °C to allow incorporation of bound
viral particles. Antiviral treatments were added at different time points after temperature shift for a total of 4 h and an intracellular anti-RSV-P staining was
performed and the number of RSV positive cells was detected by FACS analysis 24 h post infection. Repeated measures 1way ANOVA followed by test for linear trend,
with means compared from left to right within each treatment group. Mean of 3 independent experiments with standard deviation are given. C) Two different firefly-
luciferase encoding lentiviral RSV pseudotypes (red circle and blue square) or VSV-G pseudotypes (green triangle) were pretreated with increasing concentrations of
Laby A1/A2 prior to infection of A549 cells. 72 h post infection, A549 cells were lysed and the luciferase activity was measured with a tube luminometer (Lumat
LB9507; Berthold, Freiburg, Germany). Mean values and SD of at least 4 independent experiments are shown. D) RSV-ON1-H1 virus was preincubated for 1 h at room
temperature with indicated concentrations of compounds prior to serial 5-fold dilutions and infection of HEp-2 cells. 8 wells of a 96-well plate were inoculated with
the same virus dilution and 24 h post inoculation RSV-infected cells were histochemically stained with a RSV-P antibody and the virus titer was determined via
TCID50 analysis. Dashed line indicates the limit of detection (LOD). Repeated measures 1way ANOVA of logarithmic transformed values followed by Dunnett's
multiple comparison correction, with treatment means compared to DMSO control. Mean of 3 independent experiments including standard deviation is given. *,
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; n.s., not significant.
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abundance of PE in viral and host cell membranes. Alternatively or in
addition, cellular membrane repair mechanisms, which are absent in
virus particles, may prevent lethal disruption of cell membrane in-
tegrity up to very high Laby A1/A2 doses (Brito et al., 2019).
3.4. Laby A1/A2 inhibit primary RSV strains and viruses resistant to entry
inhibitors
RSV strains are classified in two antigenic subgroups (RSV-A and
RSV-B) (Anderson et al., 1985) and multiple genotypes based on the
variability of the glycoprotein G (Griffiths et al., 2017). To examine the
breadth of the anti-RSV activity of Laby A1 and A2, we used 2 addi-
tional primary clinical isolates representing the RSV subtypes B and
GA2 along with the well-known cell culture passaged RSV-A2 and RSV-
long strains. As is depicted in Fig. 4A, all primary strains were inhibited
by both Laby A1 and A2 in a dose-dependent manner and with
comparable IC50 values.
Single point mutations are sufficient for pronounced resistance of
RSV to Palivizumab (Zhao et al., 2006; Zhu et al., 2011) or fusion in-
hibitors as for instance BMS-433771 (Battles et al., 2016; Cianci et al.,
2004; Yan et al., 2014). To test cross-resistance of known resistance
mutations to Palivizumab or fusion inhibitors like BMS-433771, we
performed a lentiviral-based pseudoparticle infection assay (Fig. 4B)
(Haid et al., 2015) or infections with a RSV-ON1-H1 virus population
that is resistant to Palivizumab (Fig. 4C). Susceptibility to Laby A1/A2
was not affected by the BMS-433771 resistance mutation (K394R) and
decreased only minimally by the resistance mutations against Palivi-
zumab (K272E). However, because we did not observe cross resistance
of the RSV-ON1-H1 population to LabyA1/A2 we conclude that Laby
A1/A2 have a different mode of action that is not affected by resistance
mutations against other classes of RSV entry inhibitors.
Fig. 3. Laby A1/A2 bind to phosphatidylethanolamine and thereby destabilize the particle integrity. A) HEp-2 cells were pretreated for 30 min at 37 °C with
increasing concentrations of Laby A1/A2 and a 10% fixed concentration of liposomes with varying composition (DOPE, DOPC, DOPS red squares; DOPC, DOPS grey
circles) or without addition of liposomes (black diamonds) prior to infection with RSV-ON1-H1 at an MOI of 0.2. 24 h post inoculation, number of RSV-infected cells
was determined by intracellular RSV-P staining and subsequent FACS analysis. Mean values of 3 independent experiments and standard deviation are given. B)
Liposomes composed of DOPC alone or of a mixture of DOPC and DOPE were incubated with given amounts of Laby A1 prior to incubation with RSV luciferase
reporter virus particles. Mean values of two independent experiments are shown normalized to control infections performed in the absence of laby. C) 40 μM of Laby
A1 or DMSO were preincubated for 30 min at room temperature with 3 different concentrations (max, med, min) of either PE-containing (DOPE) or pure PC-
containing liposomes (DOPC). Subsequently, RSV-ON1-H1 virus or cell culture medium derived from uninfected cells (conditioned media) were added for another
30 min at room temperature prior to addition of proteinase K (2 μg/ml final concentration) for 1 h on ice and subsequent inactivation of the proteinase K at 98 °C for
10 min. Samples were separated on a 11% SDS-PAGE followed by Western Blot analysis using an antibody against RSV-P. One out of 2 independent experiments is
shown.
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Fig. 4. Drug-resistant mutant viruses are sensitive to Laby A1/A2 treatment. A) Clinical RSV isolates obtained from nasal lavage of RSV-infected children and subsequently
cultured on HEp-2 cells were preincubated with Laby A1/A2 at the given concentrations for 20 min prior to infection of HEp-2 cells (MOI 1) for 4 h. Infected cells were
quantified 24 h later by FACS analysis using RSV-P-specific antibodies. Means of 3 independent experiments and standard deviations are given. For RSV-B and RSV-A-GA2
only n = 2 is depicted for 20 μM Laby A2. B) A549 cells were inoculated with Renilla-luciferase expressing lentiviral RSV pseudoparticles harboring a 4 aminoacid
truncated wild type F-protein (blue circle), a truncated mutant F-protein resistant to Palivizumab treatment (purple square; K272E) or a truncated mutant F-protein resistant
to treatment with the fusion inhibitor BMS-433771 (green triangle; K394R) in the presence of indicated concentrations of Laby A1/A2. Results are normalized to solvent
treated control. Dashed lines indicate the measurement background for the individual pseudoparticles. Means of 4 independent experiments and standard deviation are
given. C) RSV-ON1-H1 virus was cultured for 5 passages in the presence of increasing concentrations of Palivizumab to generate a naturally occurring mutant virus resistant
to Palivizumab treatment (Zhu Q et al., JID2011). Amino acid exchange (K272T) in the fusion protein responsible for Palivizumab resistance has been verified by Sanger
sequencing (data not shown). Wildtype (black) and resistant mutant (white) of the RSV-ON1-H1 isolate were treated with increasing concentrations of Laby A1, Laby A2 or
Palivizumab prior to infection of HEp-2 cells. 24 h post infection, an intracellular FACS analysis against the RSV-P protein was performed. Mean values and standard
deviations of 3 independent experiments normalized to solvent control are shown.
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3.5. Synergistic effect of Laby A1/A2 in combination therapy
As resistance to RSV entry inhibitors arises rapidly, we tested
whether a combination of different inhibitors had antagonistic, ad-
ditive or synergistic effects. In Fig. 5 we display deviations from the-
oretical additive effects, which were calculated as described by Pri-
chard and Shipmann (Prichard and Shipman, 1990) for the
combination of Laby A1 with Ribavirin (Fig. 5A), Palivizumab
(Fig. 5B) or Laby A2 (Fig. 5C). None of the combinations tested ex-
erted an antagonistic effect. Combined treatment of Laby A1 with
Ribavirin was additive across the entire tested dose range (Fig. 5A).
For combination of Laby A1 with Palivizumab we observed a modest
synergistic activity in selected dose combinations. The combination of
Laby A1 with Laby A2 exerted a synergistic effect across a broad range
of doses (Fig. 5B and C). The mechanism of synergism between Laby
A1 and A2 is presently unknown, however, it is possible that these
peptides may cooperatively bind and destroy virus particles leading to
the observed synergism.
3.6. Laby A1/A2 inhibit RSV infection in primary human airway epithelial
cells and in vivo
In human ex vivo cell culture models, RSV infects well-differentiated
and polarized lung cells that form a pseudostratified epithelium of the
respiratory tract (Villenave et al., 2012). To investigate the antiviral
effect of Laby A1/A2 in this most authentic cell culture model, we in-
fected well-differentiated human primary epithelial cells grown in air-
liquid interface cultures with RSV. The cells were either treated with
Laby A1/A2 during virus inoculation (Fig. 6A), or treatment was in-
itiated 8 h post infection (Fig. 6B). The drugs were applied to the apical
side of the epithelium to mimic an inhalative administration route, and
the effect on RSV infection was analyzed by qRT-PCR. Prophylactic
treatment of RSV infection with Laby A1 and A2 significantly reduced
production of viral progeny approximately 100-fold for Laby A1 and
30-fold for Laby A2 48 h post infection (Fig. 6A). The antiviral effect
was less pronounced but still significant 72 h post infection, as the drug
was only given once. In the therapeutic regimen, treatment was in-
itiated 8 h post virus infection with subsequent twice daily treatments.
In this setting, a dose-dependent decrease in viral RNA from cell lysates
72 h post treatment onset was observed for both Laby A1 and Laby A2
(Fig. 6B), but the antiviral effect was less pronounced compared to
prophylactic treatment.
Finally, to analyze the antiviral effect of Laby A1/A2 in vivo, we
pretreated Balb/c mice intranasally with Laby A1/A2 for 1 h prior to
intranasal infection with an rHRSV-A-Luc reporter virus (Rameix-
Welti et al., 2014). Treatment was repeated daily over eight days, and
RSV infection was monitored on an IVIS machine by measuring the
luminescence signal intensity. Signal intensity was significantly lower
in the noses of animals treated with Laby A1 or A2 between days 2–6
after virus inoculation (Fig. 6C and D). However, no significant de-
crease in viral load related luminescence was detectable in the lungs of
treated animals, most probably due to poor delivery of the compounds
to the lower respiratory tract (Fig. 6C and D). One RSV-infected, ve-
hicle-treated animal but none of the Laby A1 or A2 treated mice died
during anaesthesia (day 6 post infection). Laby A1 or A2 treated an-
imals showed an initial weight loss, which was significant for Laby A1
treated compared to untreated animals, but plateaued over time
(Fig. 6E). Histological analysis did not reveal any cytotoxic effects in
the lungs of Laby A1 or A2 treated animals (data not shown) and no
further adverse drug effects were observed. It is possible that Laby A1
interactions with membrane lipids of host lung cells cause weight loss
for instance by impeding gas exchange. Future studies focus on the
development of improved drug delivery formulations for a parenteral
and/or inhalative administration and establishment of a safety profile
for both drugs.
4. Conclusion
Labyrintopeptin A1 and A2 represent a novel class of RSV entry
inhibitors with IC50's in the low micromolar range, with favourable
therapeutic index, and with efficacy against a broad range of RSV
strains including primary isolates. They exert a synergistic antiviral
activity by directly acting on virus particles, likely through binding to
virus membrane-resident phosphatidylethanolamine and through ex-
erting a virolytic effect. Due to this novel mode of action, viral re-
sistance to licensed entry inhibitors or clinical-stage virus fusion
Fig. 5. A) Antiviral effect of Laby A1 and Ribavirin drug combinations in HEp-
2 cells. The dose ranges of compounds are given. Cells were lysed 24 h post
infection with rHRSV-A-Luc virus in the presence of different drug combina-
tions and luciferase activity was measured. Luminescence values obtained from
single drug treatment were normalized to the DMSO control and the theoretical
additive effect was calculated using equations described by Prichard and
Shipman. Normalized values of combined compounds were compared to the
theoretical additive surface and the difference was plotted. Shading indicates
different ranges above or below the expected value. Mean of 2 independent
experiments is shown. B) Drug-drug interaction of Laby A1 and Palivizumab.
Mean of 2 independent experiments is given. C) Drug-drug interaction of Laby
A1 and Laby A2. Means of 3 independent experiments are given.
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inhibitors does not cause cross-resistance. Finally, Laby A1 and A2 in-
hibit RSV infection in prophylactic and therapeutic treatment regimens
in primary human lung cells and show promising activity in a murine
model in vivo.
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